Telmisartan further elicits anti-inflammatory and antiatherosclerotic effects through the activation of PPARγ, involving reduced activity of the pro-inflammatory transcription factors NF-kB and early-growth response protein (Egr)-1 [163], promotes the proliferation of endothelial progenitor cells [164], and improves microvascular dysfunction during myocardial ischemia/reperfusion injury [165] via PPARγ dependent pathways. This evidence concerns the gene PPARG and myocardial ischemia.